| Literature DB >> 35621624 |
Eva Daminato1, Giulio Bianchini2, Valerio Causin1.
Abstract
Fillers based on crosslinked hyaluronic acid (HA) are becoming increasingly important in the field of aesthetic medicine, for example for treating wrinkles or for volumizing purposes. However, crosslinking agents are usually associated with toxicity and adverse reactions. The aim of this study is the development of an innovative technology to manufacture high performance HA-based fillers using minimal amounts of crosslinking agent. In this work, new fillers based on HA, functionalized with different amounts of 1,4-butanediol diglycidyl ether (BDDE) (degree of modification ranging between 3.5% and 8.8%) and formulated with a lactose modified chitosan (CTL), were investigated. The relative quantities of these polymeric building blocks in the formulations were 20-25 and 5 mg/mL for HA and CTL, respectively. Due to its cationic nature, CTL could interact with the anionic HA and enhance the elastic properties of the filler. Fillers manufactured with this novel technology (HACL-CTL) were characterized and compared with several fillers available in the market. In particular, resistance against hyaluronidase, swelling, cohesivity and rheological properties were investigated. Cohesivity, resistance to hydrolysis and swelling of HACL-CTL were comparable to commercial products. However, HACL-CTL fillers showed excellent elastic performance that reached 94% of elasticity in response to shear stresses. Surprisingly, these fillers also showed a resistance to compression higher than that of currently marketed products, making them very promising for their lifting effect.Entities:
Keywords: chitosan; crosslinking; dermal filler; hyaluronic acid; rheology
Year: 2022 PMID: 35621624 PMCID: PMC9141296 DOI: 10.3390/gels8050326
Source DB: PubMed Journal: Gels ISSN: 2310-2861
Synthetic parameters and viscoelastic results of several samples. * Viscoelastic measurements were performed at a 1 Hz.
| Sample | HA (mg/mL) | CTL (mg/mL) | MoD% (%) | Mw HA | G′ (Pa) | G″ (Pa) | Elasticity (%) | tan δ |
|---|---|---|---|---|---|---|---|---|
| MMW-HACL-3.5 | 20 | 0 | 3.5 | 800–1500 | 27 ± 1 | 15 ± 1 | 64 ± 4 | 0.56 ± 0.04 |
| MMW-HACL-7 | 20 | 0 | 7.0 | 800–1500 | 91 ± 4 | 16 ± 1 | 85 ± 6 | 0.18 ± 0.01 |
| MMW-HACL-CTL-3.5 | 20 | 5 | 3.5 | 800–1500 | 35 ± 2 | 18 ± 1 | 66 ± 4 | 0.51 ± 0.04 |
| MMW-HACL-CTL-7.0 | 20 | 5 | 7.0 | 800–1500 | 141 ± 7 | 22 ± 1 | 86 ± 6 | 0.16 ± 0.01 |
| MMW-HACL-CTL-8.8 | 20 | 5 | 8.8 | 800–1500 | 643 ± 32 | 45 ± 2 | 93 ± 6 | 0.07 ± 0.01 |
| MMW-HACL-CTL-7.0(25) | 25 | 5 | 7.0 | 800–1500 | 425 ± 21 | 54 ± 3 | 89 ± 6 | 0.13 ± 0.01 |
| HMW-HACL-CTL-7.0 | 20 | 5 | 7.0 | >2000 | 374 ± 19 | 24 ± 1 | 94 ± 6 | 0.06 ± 0.01 |
* HA: hyaluronic acid concentration; CTL: Chitlac concentration; MoD: degree of modification as defined in par. 4.8; Mw HA: molecular weight of hyaluronic acid; G′: elastic modulus; G″: viscous modulus; tan δ: loss factor.
Viscoelastic properties at 1 Hz of selected samples produced in this work and of some commercial samples (MKT 1–6). * Sample MMW-HACL-CTL-5.7 was prepared with medium molecular weight hyaluronic acid, while HMW-HACL-CTL-3.8, HMW-HACL-CTL-6.8 and HMW-HACL-CTL-7.0 with high molecular weight hyaluronic acid.
| Sample | HA (mg/mL) | CTL (mg/mL) | MoD% (%) | G′ (Pa) | G″ (Pa) | Elasticity (%) | tan δ |
|---|---|---|---|---|---|---|---|
| MMW-HACL-CTL-5.7 | 20 | 5 | 5.7 | 141 ± 7 | 22 ± 1 | 86 ± 6 | 0.16 ± 0.01 |
| HMW-HACL-CTL-3.8 | 20 | 5 | 3.8 | 164 ± 8 | 37 ± 2 | 82 ± 6 | 0.22 ± 0.02 |
| HMW-HACL-CTL-6.8 | 20 | 5 | 6.8 | 232 ± 11 | 34 ± 2 | 87 ± 6 | 0.15 ± 0.01 |
| HMW-HACL-CTL-7.0 | 20 | 5 | 7.0 | 374 ± 19 | 24 ± 1 | 94 ± 6 | 0.06 ± 0.01 |
| MKT1 | 25 | 0 | 17.7 | 179 ± 9 | 22 ± 1 | 89 ± 6 | 0.12 ± 0.01 |
| MKT2 | 25 | 0 | 14.0 | 489 ± 24 | 133 ± 7 | 79 ± 6 | 0.27 ± 0.02 |
| MKT3 | 25 | 0 | 22.2 | 625 ± 31 | 45 ± 2 | 93 ± 6 | 0.07 ± 0.01 |
| MKT4 | 23 | 0 | 5.1 | 183 ± 9 | 55 ± 3 | 77 ± 5 | 0.30 ± 0.02 |
| MKT5 | 23 | 0 | 6.0 [ | 232 ± 11 | 52 ± 3 | 82 ± 6 | 0.22 ± 0.02 |
| MKT6 | 23 | 0 | 6.8 [ | 308 ± 15 | 40 ± 2 | 88 ± 6 | 0.13 ± 0.01 |
* HA: hyaluronic acid concentration; CTL: Chitlac concentration; MoD: degree of modification as defined in par. 4.8; G′: elastic modulus; G″: viscous modulus; tan δ: loss factor.
Figure 1Hyaluronic acid (HA) soluble fraction after incubation with Bovine Testicular Hyaluronidase (BTH) 5 U/mL at 37 °C at different times (0, 30, 60 and 300 min). MKTx samples are commercial products analyzed for comparison. For clarity and to aid comparison, error bars are shown only for some of the samples. Lines are included only to guide the eyes.
Swelling results of HACL-CTL fillers in phosphate buffer solution at 37 °C.
| Sample | Swelling |
|---|---|
| MMW-HACL-CTL-5.7 | 184 ± 19 |
| HMW-HACL-CTL-3.8 | 177 ± 12 |
| HMW-HACL-CTL-6.8 | 178 ± 15 |
| HMW-HACL-CTL-7.0 | 89 ± 8 |
Figure 2Cohesivity score in deionized water at 0, 30, 60 and 300 s of (a) commercial samples and (b) HACL-CTL fillers. Lines are added only to guide the eyes. Data regarding samples MMW-HACL-CTL-5.7 and HMW-HACL-CTL-6.8 are superimposed. Cohesivity scores are the following: 1: fully dispersed; 2: mostly dispersed; 3: partially dispersed, partially cohesive; 4: mostly cohesive; 5: fully cohesive.
Normal force (FN) exerted and elastic modulus (G′) at 1 Hz of HACL-CTL fillers and commercial products.
| Sample | FN (N) | G′ (Pa) |
|---|---|---|
| MMW-HACL-CTL-5.7 | 1.90 ± 0.05 | 141 ± 7 |
| HMW-HACL-CTL-3.8 | 2.31 ± 0.07 | 164 ± 8 |
| HMW-HACL-CTL-6.8 | 2.63 ± 0.13 | 232 ± 11 |
| HMW-HACL-CTL-7.0 | 2.84 ± 0.03 | 374 ± 19 |
| MKT1 | 0.77 ± 0.06 | 179 ± 9 |
| MKT2 | 0.83 ± 0.03 | 489 ± 24 |
| MKT3 | 1.53 ± 0.11 | 625 ± 31 |
| MKT4 | 1.12 ± 0.08 | 183 ± 9 |
| MKT5 | 1.62 ± 0.02 | 232 ± 11 |
| MKT6 | 1.47 ± 0.27 | 308 ± 15 |